Skip to content
value.today
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

AVIR
$343 Mmarket cap on Oct 29, 2026+29.9% since Jan 2024
Compare
World rank
#14,230
Revenue
—
For year ending December-2025
Net income
$-158 M
SEC filing
Employees
19
As on September 2020
value.today research

Atea Pharmaceuticals, Inc. in brief

Atea Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $343 M on 29 October 2026, which makes it the 14,230th largest listed company in the world and the 2,785th largest in the USA on this site. It employs about 19 people and Jean-Pierre Sommadossi is its chief executive. Its shares trade under the symbol AVIR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Atea Pharmaceuticals, Inc.

Atea is a Clinical Stage Biopharmaceutical company. It is focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life threatening viral diseases. The company annual revenue is 13.6 million USD and 6,904 employees as on 2019. The headquarters is in USA.

Atea Pharmaceuticals, Inc. timeline

2 events, 2013–2020
  1. 2013
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2020
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 30 October 2020; shares registered for exchange trading on 26 October 2020.

Events of Atea Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$932 M$1.9 B$2.8 B$3.7 B202120222023202420252026

World rank over time

▼ down 10,343 places since 2021
2021-01-01: #3915#3,91520212022-01-07: #11890#11,89020222022-12-25: #14183#14,18320222023-07-30: #16154#16,15420232024-01-05: #16475#16,47520242026-03-08: #7280#7,28020262026-08-01: #13030#13,03020262026-09-18: #13394#13,39420262026-10-29: #14258#14,2582026

Rank in USA: #1,255 (Jan 2021) · #2,982 (Jan 2022) · #2,911 (Dec 2022) · #3,285 (Jul 2023) · #3,040 (Jan 2024) · #1,285 (Mar 2026) · #2,651 (Aug 2026) · #2,630 (Sep 2026) · #2,789 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-35.8%
Net margin
—
Operating margin
—
Return on equity
-57.5%
Liabilities / assets
12.6%
Revenue growth
+622.5%
R&D / revenue
47.6%
Profit per employee
$-8.3 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-9M—FY18Fiscal year ending Dec 2019: revenue —, net income $-14M—FY19Fiscal year ending Dec 2020: revenue $49M, net income $-11M$49MFY20Fiscal year ending Dec 2021: revenue $351M, net income $121M$351MFY21Fiscal year ending Dec 2022: revenue —, net income $-116M—FY22Fiscal year ending Dec 2023: revenue —, net income $-136M—FY23Fiscal year ending Dec 2024: revenue —, net income $-168M—FY24Fiscal year ending Dec 2025: revenue —, net income $-158M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-181M$-158M—
Dec 2024——$-193M$-168M—
Dec 2023——$-164M$-136M—
Dec 2022——$-131M$-116M—
Dec 2021$351M+622.5%$138M$121M34.5%
Dec 2020$49M—$-11M$-11M-22.5%
Dec 2019——$-15M$-14M—
Dec 2018——$-9M$-9M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-132M——$-1.94—
Dec 2024$-136M——$-2.00—
Dec 2023$-85M——$-1.63—
Dec 2022$-121M$2M$-123M$-1.39—
Dec 2021$-87M$0M$-87M$1.37—
Dec 2020$297M$0M$297M$-0.51—
Dec 2019$-13M$0M$-13M$-1.39—
Dec 2018$-8M$0M$-8M$-0.90—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-34M—Dec ’24Three months to Mar 2025: revenue —, net income $-34M—Mar ’25Three months to Jun 2025: revenue —, net income $-37M—Jun ’25Three months to Sep 2025: revenue —, net income $-42M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-45M—Dec ’25Three months to Mar 2026: revenue —, net income $-45M—Mar ’26Three months to Jun 2026: revenue —, net income $-33M—Jun ’26Three months to Sep 2026: revenue —, net income $-32M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Atea Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-181 M
Net income
$-158 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$315 M
Total liabilities
$40 M
Total equity
$275 M

As of December-2025

Top 100 institutional investors in Atea Pharmaceuticals, Inc.#

As of Sep 30, 2026
127 institutions held 59.0 M shares (about 73.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 55.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Atea Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1FMR LLC12,030,704+26,640 (+0.22%)14.98%$63 MNov 10, 2026
2BlackRock, Inc.9,061,530+341,453 (+3.92%)11.28%$47 MNov 13, 2026
3BML Capital Management, LLC6,753,658-198,672 (-2.86%)8.41%$35 MNov 6, 2026
4Tang Capital Management LLC4,814,7000 (0.00%)6.00%$25 MNov 16, 2026
5Vanguard Capital Management LLC2,906,793-58,069 (-1.96%)3.62%$15 MNov 13, 2026
6Acadian Asset Management LLC2,338,271+303,079 (+14.89%)2.91%$12 MNov 9, 2026
7Bain Capital Life Sciences Investors, LLC2,075,6390 (0.00%)2.58%$11 MNov 16, 2026
8Geode Capital Management, LLC1,910,289-48,146 (-2.46%)2.38%$10 MNov 6, 2026
9State Street Corp1,626,938-25,461 (-1.54%)2.03%$8 MNov 12, 2026
10Two Sigma Investments, LP1,303,341-203,356 (-13.50%)1.62%$7 MNov 16, 2026
11Dimensional Fund Advisors LP1,300,324+809 (+0.06%)1.62%$7 MNov 4, 2026
12Renaissance Technologies LLC1,092,900-38,300 (-3.39%)1.36%$6 MNov 12, 2026
13Jpmorgan Chase & Co925,284-20,634 (-2.18%)1.15%$5 MNov 12, 2026
14Northern Trust Corp715,769-39,470 (-5.23%)0.89%$4 MNov 16, 2026
15Vanguard Portfolio Management LLC639,968+9,783 (+1.55%)0.80%$3 MNov 13, 2026
16Charles Schwab Investment Management Inc637,551+26,944 (+4.41%)0.79%$3 MNov 16, 2026
17Morgan Stanley556,469-163,045 (-22.66%)0.69%$3 MNov 13, 2026
18AQR Capital Management LLC493,689+245,979 (+99.30%)0.61%$3 MNov 16, 2026
19Goldman Sachs Group Inc477,579-53,277 (-10.04%)0.59%$2 MNov 16, 2026
20Vanguard Fiduciary Trust Co469,723-78 (-0.02%)0.58%$2 MNov 13, 2026
21CM Management, LLC450,000+95,000 (+26.76%)0.56%$2 MNov 12, 2026
22Rock Springs Capital Management LP433,620New0.54%$2 MNov 16, 2026
23D. E. Shaw & Co., Inc.353,494+8,308 (+2.41%)0.44%$2 MNov 16, 2026
24Banque Pictet & Cie SA345,0770 (0.00%)0.43%$2 MOct 16, 2026
25Arrowstreet Capital, Limited Partnership322,668+112,126 (+53.26%)0.40%$2 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Atea Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Rosalind Advisors, Inc.280,061-790,489 (-73.84%)0.35%$1 MNov 16, 2026
27Invesco Ltd.254,337-12,788 (-4.79%)0.32%$1 MNov 12, 2026
28Quantinno Capital Management LP251,935+9,633 (+3.98%)0.31%$1 MNov 13, 2026
29Nuveen, LLC247,657-36,626 (-12.88%)0.31%$1 MNov 10, 2026
30Wellington Management Group LLP246,582+39,797 (+19.25%)0.31%$1 MNov 16, 2026
31Susquehanna International Group, LLP245,456+231,746 (+1690.34%)0.31%$1 MNov 16, 2026
32HSBC Holdings PLC240,650+19,641 (+8.89%)0.30%$1 MNov 16, 2026
33Bank of New York Mellon Corp196,724+7,272 (+3.84%)0.24%$1 MNov 5, 2026
34Barclays PLC175,465-173,188 (-49.67%)0.22%$1 MNov 6, 2026
35Auour Investments LLC172,000-5,000 (-2.82%)0.21%$1 MOct 28, 2026
36Strs Ohio171,100+53,400 (+45.37%)0.21%$1 MOct 30, 2026
37American Century Companies Inc170,291-366 (-0.21%)0.21%$1 MNov 12, 2026
38Millennium Management LLC159,884-144,727 (-47.51%)0.20%$1 MNov 16, 2026
39UBS Group AG147,948+53,441 (+56.55%)0.18%$1 MNov 10, 2026
40Bridgeway Capital Management, LLC129,356-1,544 (-1.18%)0.16%$1 MNov 16, 2026
41Alliancebernstein L.P.117,720-6,500 (-5.23%)0.15%$1 MNov 16, 2026
42State Of Wisconsin Investment Board117,357-1,400 (-1.18%)0.15%$1 MNov 16, 2026
43Price T Rowe Associates Inc /MD/115,8080 (0.00%)0.14%$1 MNov 16, 2026
44Bank Of America Corp /de/108,838+27,108 (+33.17%)0.14%$1 MNov 16, 2026
45Empowered Funds, LLC91,256New0.11%$0 MNov 13, 2026
46Rhumbline Advisers88,042-3,082 (-3.38%)0.11%$0 MNov 10, 2026
47Aldebaran Capital, LLC86,068-2,112 (-2.40%)0.11%$0 MNov 13, 2026
48Nomura Asset Management International Inc.70,0000 (0.00%)0.09%$0 MNov 16, 2026
49Deutsche Bank AG\61,593-8,807 (-12.51%)0.08%$0 MNov 6, 2026
50Susquehanna Portfolio Strategies, LLC57,502-4,571 (-7.36%)0.07%$0 MNov 16, 2026
51Russell Investments Group, Ltd.55,358+466 (+0.85%)0.07%$0 MNov 6, 2026
52Trexquant Investment LP54,908+40,157 (+272.23%)0.07%$0 MNov 16, 2026
53Creative Planning50,876+27,773 (+120.21%)0.06%$0 MNov 2, 2026
54WINTON GROUP Ltd43,700New0.05%$0 MNov 12, 2026
55Rangeley Capital, LLC41,500-2,000 (-4.60%)0.05%$0 MNov 16, 2026
56Nano Cap New Millennium Growth Fund L P35,0000 (0.00%)0.04%$0 MNov 13, 2026
57Simplex Trading, LLC34,225+31,292 (+1066.89%)0.04%$0 MNov 4, 2026
58MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.33,856+1,198 (+3.67%)0.04%$0 MNov 16, 2026
59MetLife Investment Management, LLC30,136-9,330 (-23.64%)0.04%$0 MNov 16, 2026
60RBF Capital, LLC30,0000 (0.00%)0.04%$0 MNov 13, 2026
61Mercer Global Advisors Inc /adv27,650-210 (-0.75%)0.03%$0 MNov 16, 2026
62Vanguard Global Advisers, LLC26,040+359 (+1.40%)0.03%$0 MNov 13, 2026
63Certified Advisory Corp24,5000 (0.00%)0.03%$0 MOct 29, 2026
64Spark Investment Management LLC24,100+7,900 (+48.77%)0.03%$0 MNov 13, 2026
65XTX Topco Ltd24,055New0.03%$0 MNov 16, 2026
66BNP Paribas Financial Markets23,983-54,738 (-69.53%)0.03%$0 MNov 12, 2026
67State Board Of Administration Of Florida Retirement System22,0100 (0.00%)0.03%$0 MNov 13, 2026
68Quadrature Capital Ltd20,398New0.03%$0 MNov 13, 2026
69SEI Investments Co19,0380 (0.00%)0.02%$0 MNov 10, 2026
70Manufacturers Life Insurance Company, The17,816+118 (+0.67%)0.02%$0 MNov 13, 2026
71Engineers Gate Manager LP17,077+271 (+1.61%)0.02%$0 MNov 16, 2026
72Police & Firemen's Retirement System of New Jersey16,9380 (0.00%)0.02%$0 MNov 9, 2026
73New York State Common Retirement Fund16,3460 (0.00%)0.02%$0 MNov 17, 2026
74Voya Investment Management LLC16,2420 (0.00%)0.02%$0 MNov 10, 2026
75Bailard, Inc.16,1000 (0.00%)0.02%$0 MOct 13, 2026
76RFG Advisory, LLC14,8750 (0.00%)0.02%$0 MNov 3, 2026
77Citadel Advisors LLC14,850-142,374 (-90.55%)0.02%$0 MNov 16, 2026
78China Universal Asset Management Co., Ltd.14,634+1,898 (+14.90%)0.02%$0 MOct 28, 2026
79Wells Fargo & Company/mn13,889-45,827 (-76.74%)0.02%$0 MNov 16, 2026
80Mariner, LLC12,848New0.02%$0 MNov 12, 2026
81Prudential Financial Inc12,1800 (0.00%)0.02%$0 MNov 16, 2026
82Dynamic Technology Lab Private Ltd12,104New0.02%$0 MNov 13, 2026
83Sunpointe, LLC11,9430 (0.00%)0.01%$0 MOct 22, 2026
84ProShare Advisors LLC11,685-222 (-1.86%)0.01%$0 MOct 29, 2026
85Wealth Enhancement Advisory Services, LLC11,266New0.01%$0 MOct 13, 2026
86Blair William & Co/il11,025-300 (-2.65%)0.01%$0 MNov 10, 2026
87Fox Run Management, L.L.C.10,245New0.01%$0 MNov 12, 2026
88M&T Bank Corp10,130New0.01%$0 MNov 10, 2026
89UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC9,207+6,888 (+297.02%)0.01%$0 MNov 16, 2026
90Blue Trust, Inc.8,7000 (0.00%)0.01%$0 MOct 15, 2026
91Legal & General Group Plc7,0820 (0.00%)0.01%$0 MNov 16, 2026
92Citigroup Inc6,754-27,860 (-80.49%)0.01%$0 MNov 4, 2026
93Group One Trading LLC6,538+6,398 (+4570.00%)0.01%$0 MNov 10, 2026
94Ameritas Investment Partners, Inc.5,9140 (0.00%)0.01%$0 MNov 13, 2026
95FNY Investment Advisers, LLC5,0000 (0.00%)0.01%$0 MOct 16, 2026
96PNC Financial Services Group, Inc.4,544+1,759 (+63.16%)0.01%$0 MNov 6, 2026
97Arax Advisory Partners4,484+260 (+6.16%)0.01%$0 MNov 12, 2026
98Versant Capital Management, Inc4,397+177 (+4.19%)0.01%$0 MOct 2, 2026
99Mirae Asset Global Investments Co., Ltd.4,099+520 (+14.53%)0.01%$0 MOct 29, 2026
100Royal Bank Of Canada3,790+572 (+17.78%)0.00%$0 MNov 16, 2026

All 127 institutional investors, with who bought and sold →

Mutual funds holding Atea Pharmaceuticals, Inc.#

134 funds hold shares worth $89 M (about 23.7% of the company). Since their previous reports 42 added shares and 39 sold, buying $3 M net.
Mutual funds holding Atea Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC3.10 M$14 M3.9%0.01%+21%May 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.03 M$9 M2.5%<0.01%−14%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.84 M$9 M2.3%0.01%+6.4%Jun 30, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC1.22 M$6 M1.5%0.02%−0.5%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.865,318$4 M1.1%<0.01%+7.0%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC771,325$4 M0.96%0.01%+12%Jul 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC733,900$3 M0.91%0.01%+22%May 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors669,481$3 M0.83%0.02%+13%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC613,370$3 M0.76%0.05%−1.2%May 29, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors437,948$2 M0.55%0.02%−4.8%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.358,829$2 M0.45%<0.01%+1.8%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP349,976$2 M0.44%<0.01%no changeJul 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.345,893$2 M0.43%<0.01%−1.6%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC313,724$1 M0.39%<0.01%−12%May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC287,662$1 M0.36%0.03%+21%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP263,930$1 M0.33%<0.01%no changeJul 31, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.243,540$1 M0.30%0.10%−6.7%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors238,228$1 M0.30%0.07%+35%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP234,809$1 M0.29%0.01%no changeJul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors180,290$1 M0.22%<0.01%−3.3%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.172,263$1 M0.21%0.01%+13%Jul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.153,768$1 M0.19%<0.01%−0.8%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust151,732$1 M0.19%0.03%+2.5%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC148,672$1 M0.19%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds142,812$1 M0.18%0.08%−0.1%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC138,233$1 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC131,975$1 M0.16%0.01%+25%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.125,715$1 M0.16%0.04%−5.7%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC110,737$1 M0.14%<0.01%−1.5%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC107,781$1 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.104,395$0 M0.13%0.07%newJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC98,939$0 M0.12%0.02%+14%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC94,351$0 M0.12%<0.01%no changeJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC92,800$0 M0.12%0.29%−16%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC89,888$0 M0.11%0.01%no changeJul 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.82,125$0 M0.10%0.24%+18%May 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP81,300$0 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC70,280$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company70,000$0 M0.09%0.04%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC69,618$0 M0.09%<0.01%−28%May 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC65,990$0 M0.08%0.02%+4.6%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP58,155$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Invesco BuyBack AchieversTM ETFInvesco Capital Management LLC57,412$0 M0.07%0.01%+25%Jul 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.56,800$0 M0.07%0.02%no changeJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC54,498$0 M0.07%<0.01%−10.0%Jul 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation54,347$0 M0.07%0.10%−5.4%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.54,047$0 M0.07%0.02%+4.7%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC52,533$0 M0.07%<0.01%−9.2%May 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors51,459$0 M0.06%<0.01%−24%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation48,000$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.47,410$0 M0.06%<0.01%+1.0%May 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC45,730$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.45,000$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.42,851$0 M0.05%<0.01%−25%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC41,180$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC36,692$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.35,845$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC35,773$0 M0.04%0.05%−5.0%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC33,880$0 M0.04%0.01%+12%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.34,065$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.31,847$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC30,925$0 M0.04%0.04%−14%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company30,676$0 M0.04%0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC30,304$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC27,358$0 M0.03%<0.01%+11%Jul 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company25,608$0 M0.03%0.05%−11%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.23,200$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC22,588$0 M0.03%<0.01%−1.4%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC21,416$0 M0.03%0.01%no changeJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC20,922$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors18,297$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC17,888$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP16,803$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP16,361$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS16,504$0 M0.02%0.01%+23%Jun 30, 2026
🇺🇸 Nationwide Bailard Small Cap Value FundNATIONWIDE FUND ADVISORS16,100$0 M0.02%0.06%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC15,830$0 M0.02%0.03%+26%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION15,000$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,244$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC14,243$0 M0.02%0.04%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC13,884$0 M0.02%<0.01%+16%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC13,029$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Common Stock Index PortfolioEquitable Investment Management Group, LLC12,500$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC11,600$0 M0.01%<0.01%−9.4%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC11,445$0 M0.01%0.01%+7.2%Jul 31, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC11,480$0 M0.01%0.04%−9.1%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.11,130$0 M0.01%0.01%+12%Jun 30, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust11,053$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.10,817$0 M0.01%0.01%+20%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC10,669$0 M0.01%0.01%+19%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC10,228$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC9,805$0 M0.01%0.02%newMay 31, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP9,202$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC8,884$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP8,300$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP7,814$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC7,400$0 M<0.01%<0.01%−21%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.7,314$0 M<0.01%<0.01%+1.8%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC7,281$0 M<0.01%<0.01%+1.6%Jul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS7,042$0 M<0.01%0.01%+35%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Atea Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$168 K
3 sales, 1 insider
Net, 12 months
-$168 K
open market only
Insiders on file
16
since
$81 K-$1.0 M$0Feb 2024: bought $0 (0 trades), sold $488 K (6 trades)Feb 24Jun 2024: bought $0 (0 trades), sold $65 K (2 trades)JunSep 2024: bought $0 (0 trades), sold $234 K (3 trades)SepDec 2024: bought $0 (0 trades), sold $1.0 M (1 trades)DecJan 2025: bought $81 K (2 trades), sold $0 (0 trades)Jan 25May 2025: bought $25 K (1 trades), sold $0 (0 trades)MayNov 2026: bought $0 (0 trades), sold $168 K (3 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Atea Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Bruce PolskyDirectorOption exercise+18,252$1.240$23 K176,832Form 4
filed Bruce PolskyDirectorSell-18,252$3.950$72 K158,580Form 4
filed Bruce PolskyDirectorOption exercise+8,720$1.240$11 K167,300Form 4
filed Bruce PolskyDirectorSell-8,720$4.032$35 K158,580Form 4
filed Bruce PolskyDirectorOption exercise+48,028$1.240$60 K172,834Form 4
filed Bruce PolskyDirectorSell-14,254$4.268$61 K158,580Form 4
filed Franklin M. BergerDirectorOption exercise+29,600——536,097Form 4
filed Bruce PolskyDirectorOption exercise+29,600——124,806Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Atea Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.0 M
3.9% of shares · 9.55 days to cover
Buybacks, Q4 2025
$0M
Q4 2025
Shares sold short, last 24 reportsAll stocks →
Atea Pharmaceuticals, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2025Q4 2025$0M
Q3 2025Q3 2025$11.4M

Trading halts

  • 2026-07-28 10:55 UTC, code T3, resumed 11:30 UTC

Fails to deliver

  • : 566 shares at $4.27
  • : 1,237 shares at $5.26
  • : 80 shares at $5.27
  • : 2 shares at $4.81
  • : 72 shares at $4.87

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Atea Pharmaceuticals, Inc. scorecard#

Passes 4 of the 13 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.94 vs -2.00Diluted EPS -1.94 in fiscal 2025 against -2.00 the year before (report's currency).
    • ✗Net income higher than five years earlier-$158 M-$158 M in fiscal 2025 against -$11 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$158 MNet income -$158 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-44.3%-44.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities7.8×Current ratio 7.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns2 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-3.3%Diluted shares down 3.3% in fiscal 2025.
    • ✓Dividends and buybacks above 3% of the market value7.4%Dividends and buybacks were 7.4% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Atea Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Atea Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue————35149——
Research and development1481441148216738106.7
General and administrative3349504946224.42.8
Operating expenses18119316413121360159.5
Operating income−181−193−164−131138−11−15−9.5
Income before tax−165−167−135−119139−11−14—
Income tax−6.20.91.0−3.617———
Net income including minority interests−158−168−136−116121−11−14−9.1
Net income attributable to shareholders−158−168−136−116121−11−14−9.1
Earnings per share, basic-1.94-2.00-1.63-1.391.46-0.51-1.39-0.90
Earnings per share, diluted-1.94-2.00-1.63-1.391.37-0.51-1.39-0.90
Shares, weighted average (basic)81848383832210—
Shares, weighted average (diluted)8184838388221010
Balance sheet
Cash and cash equivalents9665144188764850r2234
Short-term investments206390434458————
Other current assets9.27.612148.07.50.2—
Current assets31146259066177286322—
Property, plant and equipment0.50.91.31.70.00.00.0—
Right-of-use (leased) assets0.61.21.82.40.2———
Total assets31546559566777386422—
Accounts payable134.54.32.64.50.10.5—
Current liabilities40193218573162.4—
Lease liabilities (non-current)00.81.62.4————
Total liabilities40264026633162.5—
Retained earnings−523−364−196−6056−65−54—
Shareholders' equity275439555641710548−50−36
Total liabilities and equity31546559566777386422—
Shares outstanding78848383838210—
Cash-flow statement
Depreciation and amortization0.40.40.40.30.00.00.00.0
Share-based compensation21524947407.50.60.4
Cash from operating activities−132−135−85−121−87297−13−7.9
Capital expenditure———−1.9−0.0−0.0−0.0−0.0
Cash from investing activities1895640−455−0.0−0.0−0.0−0.0
Shares issued————1.50.0—0.1
Shares bought back−260——————
Cash from financing activities−260.30.30.41.5532—27
Change in cash31−79−45−576−86828−1320
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Atea Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.4 M
Jean-Pierre Sommadossi
Other top executives, average
$1.6 M
the CEO earned 2.2× this
$100 invested is now
$9
peer group: $125
Atea Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Jean-Pierre Sommadossi$3.4 M$3.6 M$1.6 M$9 (peers $125)
2024Jean-Pierre Sommadossi$4.2 M$4.3 M$1.8 M$8 (peers $93)
2023Jean-Pierre Sommadossi$5.9 M$3.4 M$1.9 M$7 (peers $94)
2022Jean-Pierre Sommadossi$5.9 M$705 K$1.9 M$12 (peers $90)
2021Jean-Pierre Sommadossi$34.1 M−$1.5 M$8.0 M$21 (peers $100)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Atea Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · New debt 1 · Shareholder vote 3 · Results announced 16

Atea Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreementNew debt8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officersMaterial agreementResults announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Atea Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$108 MNo. 4$50 to $250 million37equitySEC
Jun 2018$28 MNo. 3$10 to $50 million38equitySEC
Aug 2016$21 MNo. 2$10 to $50 million29equitySEC
Dec 2013$20 MNo. 1$10 to $50 million59equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Atea Pharmaceuticals, Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$20 K
#1,432 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$30 K
  • Health Issues2 reports

Lobbying firms hired in 2025

JEFFREY J. KIMBELL & ASSOCIATES, INC. $20 K

Atea Pharmaceuticals, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$30 K—3
2025$20 K—2
2024$60 K—6
2023$320 K—12
2022$230 K—10
2021$190 K—8
2020$150 K—6

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atea Pharmaceuticals” and “Atea Pharmaceuticals, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Atea Pharmaceuticals, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $162 K a year.

Certified, FY2025
1
#1,912 among companies on value.today
Worker positions
1
Median wage offered
$162 K
a year, full-time
Applications filed
1
Atea Pharmaceuticals, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Associate Director, Quality ControlChemists1$162 K

Where: Boston, MA 1

Atea Pharmaceuticals, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$162 K1
FY202011$160 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Atea Pharmaceuticals, Inc.

How Atea Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$343 M · higher than 53% of 726
  • Revenue growth622.5% · higher than 95% of 438
  • Price / book1.2× · lower than 74% of 534
  • FCF yield-35.9% · higher than 31% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Atea Pharmaceuticals, Inc.🇺🇸$343 M——+622.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on September 2020
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Atea Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Atea Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Atea Pharmaceuticals, Inc.? Suggest a correction